J8521 HCPCS code: Capecitabine, oral, 500 mg
J8521 is the HCPCS Level II code for capecitabine, oral, 500 mg. CMS terminated J8521 on 2024-09-30; do not bill it for later dates of service. In 2024 Medicare paid an average of $0.05 per service for J8521 across 53,315,610 services. Its Medicare coverage code is D (Special coverage instructions apply): May be covered when national or local coverage criteria are met. Medicare volume rose 549% from 2022 to 2024 (8,218,391 to 53,315,610 services). In 2024, 1,172 suppliers billed Medicare for J8521 (purchases), serving 18,039 beneficiaries; California, Florida, New York accounted for 27% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1D — Chemotherapy |
| Added | 2000-01-01 |
| Last action effective | 2024-10-01 |
| Terminated | 2024-09-30 |
Who bills J8521 (2024)
| Measure | Value |
|---|---|
| Suppliers billing rentals | — |
| Suppliers billing purchases | 1,172 |
| Referring clinicians | 8,428 |
| Medicare beneficiaries | 18,039 |
| States with claims | 53 |
| Share of services in top 3 states (California, Florida, New York) | 27% |
| Year | Suppliers | Beneficiaries |
|---|---|---|
| 2022 | 1,451 | 24,547 |
| 2023 | 1,329 | 22,865 |
| 2024 | 1,172 | 18,039 |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J8521, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 8,218,391 | 24,547 | $0.92 | $0.70 |
| 2023 | 7,415,744 | 22,865 | $6.18 | $4.81 |
| 2024 | 53,315,610 | 18,039 | $0.07 | $0.05 |
States with the most J8521 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| California | 6,882,650 | $0.05 |
| Florida | 3,894,230 | $0.05 |
| New York | 3,641,690 | $0.05 |
| Texas | 3,013,550 | $0.05 |
| Pennsylvania | 2,549,730 | $0.05 |
What changed for J8521
- 2000-01-01: J8521 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J8521?
J8521 is the HCPCS Level II code for capecitabine, oral, 500 mg. Short descriptor: "Capecitabine, oral, 500 mg".
How much does Medicare pay for J8521?
In 2024, the average Medicare payment was $0.05 per service (average allowed $0.07).
Does Medicare cover J8521?
Coverage code D — Special coverage instructions apply. May be covered when national or local coverage criteria are met.
Related J85 codes
- J8501 — Aprepitant, oral, 5 mg
- J8502 — Injection, aprepitant (aponvie), 1 mg
- J8510 — Busulfan; oral, 2 mg
- J8515 — Cabergoline, oral, 0.25 mg
- J8520 — Capecitabine, oral, 150 mg
- J8522 — Capecitabine, oral, 50 mg
- J8530 — Cyclophosphamide; oral, 25 mg
- J8540 — Dexamethasone, oral, 0.25 mg
- J8541 — Dexamethasone (hemady), oral, 0.25 mg
- J8560 — Etoposide; oral, 50 mg
- J8562 — Fludarabine phosphate, oral, 10 mg
- J8565 — Gefitinib, oral, 250 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J8521
- Watch J8521 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J8521
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.